Cerus Endovascular has announced that it has received CE mark approval for its CerusEndo MC 021 microcatheter, designed to allow physicians to access tortuous neurovasculature and deliver therapeutic devices to intended targets.
The CerusEndo MC 021 microcatheter, which already received approval from the US Food and Drug Administration (FDA), is the first of Cerus Endovascular’s microcatheter offerings to gain European regulatory approval. The device will be available in multiple distal flexible profiles and is designed to offer superior proximal support, which translates to enhanced deliverability and responsiveness in physicians’ hands. According to a company press release, feedback from numerous physicians during the development of the device was extremely encouraging when performing benchtop evaluations in highly tortuous anatomical simulations compared to other commercially available catheters.
In the company news release, Stephen Griffin, president of Cerus Endovascular, comments: “We remain committed to meeting the ever-increasing needs of the interventional neuroradiologist community. Our team has identified a range of increased performance demands required of a go-to intracranial access microcatheter.
“As a result, we have expanded our key 021 platform so that it can deliver a wider range of devices than it was originally designed for including stents, braided flow diverters, and stentrievers, for treatment of both haemorrhagic and ischaemic strokes. In particular, the 021 ensures predictable stability and control when delivering larger and braided devices through the device lumen.”
